全球动物保健巨头Zoetis（硕腾）发起对动物基因检测公司Neogen的收购，该交易正在接受多个司法管辖区的反垄断审查。
机遇：大型企业进入意味着马属基因检测从"小众科研"走向"商业标配"，市场教育成本降低。
风险：当上游巨头同时掌握药品、疫苗和基因检测时，独立实验室可能面临数据获取受限、技术标准集中等挑战。
独立实验室的价值：GenoMatrix定位为"独立数据基础设施提供商"——不卖药品、不卖疫苗，核心资产是数据和模型。这意味着数据中立性、技术开放性和创新灵活性。
GenoMatrix已就Zoetis收购Neogen案向新西兰商务委员会提交反垄断意见书。我们相信：马属基因组学需要多元化参与者，而非单一巨头的垂直整合。
Global animal health giant Zoetis has initiated the acquisition of genetic testing company Neogen, a transaction currently under antitrust review in multiple jurisdictions.
Opportunity: Large enterprise entry means equine genetic testing is transitioning from "niche research" to "commercial standard," reducing market education costs.
Risk: When upstream giants simultaneously control pharmaceuticals, vaccines, and genetic testing, independent labs may face restricted data access and concentrated technology standards.
Value of Independent Labs: GenoMatrix is positioned as an "independent data infrastructure provider" — we don't sell drugs or vaccines. Our core assets are data and models, ensuring data neutrality, technical openness, and innovation flexibility.
GenoMatrix has submitted an antitrust opinion to the NZCC regarding the Zoetis-Neogen acquisition. We believe: equine genomics needs diverse participants, not vertical integration by a single giant.